Navigation Links
A Better Acetabular Solution from StelKast ... Naturally
Date:4/15/2011

MCMURRAY, Pa., April 15, 2011 /PRNewswire/ -- StelKast is proud to announce the recent FDA 510(k) clearance of their new EXp™ Acetabular Liners. EXp™, a blend of antioxidant and highly cross-linked polyethylene technology was developed with the consulting support of Steven Kurtz, Ph.D. and Exponent, Inc. (Philadelphia, PA). StelKast has also received 510(k) clearance for large diameter cobalt-chrome femoral heads and Biolox® delta femoral heads.

(Logo:  http://photos.prnewswire.com/prnh/20110415/LA83876LOGO)

Mr. Peter Stephans, Chairman & CEO, said in a statement, "EXp™ polyethylene technology represents an optimal blend of UHMWPE, the antioxidant vitamin E (alpha-tocopherol), and cross-linking for long-term oxidative stability, preservation of mechanical properties and performance. Unlike other highly cross-linked materials, EXp™ polyethylene requires no thermal processing or infusion of antioxidants to stabilize the material. The combination of EXp™ Acetabular Liners and large diameter heads promotes joint stability.

"StelKast is excited to be the first US orthopedic company to provide a highly crosslinked vitamin E blended acetabular system offering superior oxidation resistance. The introduction of EXp™ polyethylene is just another example of StelKast's commitment to place emerging technology and high quality implants in surgeon's hands through cost effective solutions."

Full commercial launch of the EXp™ Acetabular System is planned for July 2011. For inquiries, please contact your local StelKast representative or Customer Service at 888-273-1583.

StelKast specializes in the design, manufacture, and distribution of hip and knee implant systems. The Company's mission is to provide high-quality, cost effective solutions to meet the challenges of the orthopedic community through clinically proven design concepts and innovative technology. For more information about StelKast, please visit the company website at www.stelkast.com.

Source: StelKast Inc.
Ph 888.273.1583
Fax 724.941.5987
200 Hidden Valley Road
McMurray, PA 15317 USA
www.stelkast.com


'/>"/>
SOURCE StelKast Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
2. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
3. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
6. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
7. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... BOSTON , March 28, 2017 /PRNewswire/ ... today announced a partnership with premium news ... allows pharmaceutical companies to extract key insights from ... text mining technology. The Linguamatics I2E ... top 20 global pharmaceutical companies. The Linguamatics-Dow Jones ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
(Date:3/28/2017)... March 28, 2017 Elysium Health ... Cambridge academic scientists ... The Milner Therapeutics Institute today announces Elysium Health ... has committed significant investment for collaborative projects with academic researchers ... years. This is the first major research investment outside the ...
Breaking Medicine Technology:
(Date:3/28/2017)... Lithuania (PRWEB) , ... March 28, 2017 , ... ... technologies, today announced the release of two biometric time and attendance tracking products: ... Attendance 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort to ... recently developed and published an informational resource that addresses frequently asked questions. ... inquiries the site’s team of third party administrator (TPA) contributors regularly receives as ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... more patients desire to achieve the “perfect smile.” The National Association of Dental ... well as what dentists should be aware of when utilizing dental laboratories and ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Silicon ... is proud to announce a new blog post about women’s hair loss. Although hair ... from hair loss as they age. Menopause or genetics can be two reasons a ...
Breaking Medicine News(10 mins):